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Abstract
Enterococcus faecalis BM4518 is resistant to vancomycin by synthesis of peptidoglycan
precursors ending in D-alanyl-D-serine. In the chromosomal vanG locus, transcription of the
resistance genes from the PYG resistance promoter is inducible and, upstream from these
genes, there is an unusual three-component regulatory system encoded by the vanURSG
operon from the PUG regulatory promoter. In contrast to the other van operons in enterococ-
ci, the vanG operon possesses the additional vanUG gene which encodes a transcriptional
regulator whose role remains unknown. We show by DNase I footprinting, RT-qPCR, and
reporter proteins activities that VanUG, but not VanRG, binds to PUG and negatively autore-
gulates the vanURSG operon and that it also represses PYG where it overlaps with VanRG
for binding. In clinical isolate BM4518, the transcription level of the resistance genes was
dependent on vancomycin concentration whereas, in a ΔvanUGmutant, resistance was ex-
pressed at a maximum level even at low concentrations of the inducer. The binding competi-
tion between VanUG and VanRG on the PYG resistance promoter allowed rheostatic
activation of the resistance operon depending likely on the level of VanRG phosphorylation
by the VanSG sensor. In addition, there was cross-talk between VanSG and VanR'G, a
VanRG homolog, encoded elsewhere in the chromosome indicating a sophisticated and
subtle regulation of vancomycin resistance expression by a complex two-component
system.
Author Summary
Various modes of gene regulation coexist in cells. One corresponds to the “switch on/ off”
mechanism in which the regulator induces the promoter to a defined level. In another
mechanism, the regulator activates the promoter to various levels according to the intensity
or the nature of an input signal. In this study, we show that in VanG-type vancomycin re-
sistant Enterococcus faecalis a repressor (VanUG) allows rheostatic expression of a target
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resistance promoter by competing with a response regulator (VanRG) which otherwise acts
together with a sensor (VanSG) by a "switch on/off" mechanism as part of a two-component
regulatory system. Unusually, both regulators are encoded in the same operon.
Introduction
Vancomycin-resistant enterococci are a major cause of nosocomial infections and an impor-
tant public health problem because the treatment options for the infections they cause are very
limited [1]. Vancomycin, which can be the only antibiotic effective against multiresistant clini-
cal isolates, acts by binding to the C-terminal D-alanyl-D-alanine (D-Ala-D-Ala) residues of
peptidoglycan precursors blocking the extracellular steps in peptidoglycan synthesis [2]. Resis-
tance in Enterococcus is mediated by nine types of operons that produce modified peptidogly-
can precursors ending in D-Ala-D-Lac (vanA, -B, -D, and-M) or D-Ala-D-Ser (vanC, -E, -G,
-L, and-N) to which vancomycin bind with a low affinity and from the elimination of the high
affinity precursors ending in D-Ala-D-Ala [3–6].
Expression of the vancomycin resistance operons is regulated by VanS/VanR-type two-
component signal transduction systems composed of a membrane-bound histidine kinase
(VanS-type) and a cytoplasmic response regulator (VanR-type) that acts as a transcriptional
activator [3]. The sensors modulate the levels of phosphorylation of the regulators. In the pres-
ence of vancomycin, VanS acts primarily as a kinase that autophosphorylates and transfers its
phosphate to VanR. Phosphorylated VanR binds to the promoters upstream from the vanRS
regulatory and resistance operons leading to increased transcription of the regulatory and resis-
tance genes [7–9]. The phosphatase activity of VanS-type sensors is required for negative regu-
lation of the resistance genes in the absence of vancomycin preventing accumulation of VanR-
type regulators phosphorylated by acetylphosphate or by kinases encoded by the host chromo-
some [7, 10].
VanG-type Enterococcusfaecalis clinical isolates from Australia and Canada are distinct
from other Van-type enterococci. The chromosomal vanG cluster (Fig 1) confers resistance to
vancomycin (MICs, 16 μg/ml) by inducible synthesis of precursors ending in D-Ala-D-Ser
[11]. It contains the vanYG,WG,G,XYG,TG resistance genes, the last three strictly required for
resistance encode, respectively, a VanG ligase to synthesize D-Ala-D-Ser, a VanXYG D,D-
carboxypeptidase to hydrolyse D-Ala-D-Ala, and a VanTG membrane bound serine racemase
to produce D-Ser (Fig 1). As opposed to the other van gene clusters, the vanG regulatory oper-
on contains three genes, vanUG, vanRG, and vanSG, encoding a "three component" regulatory
system (Fig 1). Additional gene vanUG encodes a transcriptional regulator belonging to the Xre
protein family and of unknown function. The vanURSG genes are co-transcribed, even in the
Fig 1. Schematic representation of the vanG operon.Open arrows represent coding sequences and
indicate direction of transcription. The regulatory genes are in red, the resistance genes in blue and
accessory genes in green. The additional regulatory gene, vanUG, is in yellow. The vertical bar in vanYG
indicates a frameshift mutation leading to a truncated protein.
doi:10.1371/journal.pgen.1005170.g001
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absence of vancomycin, from the PUG regulatory promoter, whereas transcription of the resis-
tance genes is inducible and initiated from the PYG resistance promoter [11].
Cryptic vanG-like operons are common in Clostridium difficile, a major human pathogen
which is a target for vancomycin, and a vanUG gene encoding a protein identical to VanUG
was found in a clinical isolate (GenBank N° AVLW01000050). A VanUG-like protein (Gen-
Bank N° YP002939420), 79% identical with VanUG, was detected in an Eubacterium associated
with a two-component system controlling an ABC-type transporter and a protein (GenBank
N°YP007781704) with 76% identity was reported in Ruminococcus bromii associated with a
CheY related regulator and a partial vanG operon. These regulators have not been studied.
We report the role of VanUG in the transcription of the vanG operon in E.faecalis. We show
that VanUG binds to the PUG regulatory and PYG resistance promoters and negatively regulates
the vanURSG regulatory and resistance operons. In contrast, VanRG binds only to PYG. It thus
appears that, upon induction by vancomycin, the VanSG sensor phosphorylates VanRG which
competes and displaces VanUG from PYG leading to transcription of the resistance operon in a
dose dependent manner. Thus, rheostatic regulation of resistance gene expression results from
binding of a repressor and an activator encoded in a single operon to the same promoter.
Results
VanUG but not VanRG binds to the PUG regulatory promoter
Primer extension of the region upstream from vanUG indicated that, irrespective of induction,
the transcriptional start site for vanURSG was located 22 bp upstream from the translation ini-
tiation codon of vanUG [11]. The PUG promoter consists of -35 and -10 regions corresponding
to δ70 recognition sequences separated by 17 bp (Fig 2A). To determine if VanUG and VanRG
bind to the PUG regulatory promoter region and to identify putative specific binding sites,
DNaseI footprinting experiments were carried out. A radiolabeled PCR probe corresponding
to positions -247 to +110 relative to the transcription initiation site of PUG was incubated with
increasing amounts of purified VanUG, VanRG, and VanRG phosphorylated (VanRG-P) by ace-
tyl phosphate. The PUG region protected by VanUG depended on the protein concentration, ex-
tending from -70 to -20 (positions relative to the transcription initiation site) overlapping the
-35 sequence at a low concentration (Fig 2B, lane 6) and from -70 to +10 at higher concentra-
tions (Fig 2B, lanes 7 and 8). The region (-70 to -20) contained two adjacent imperfect palin-
dromic sequences likely corresponding to the binding motifs of VanUG (Fig 2A). As opposed
to the wild-type fragment, two DNA fragments containing double mutations in the imperfect
dyad symmetry operator of PUG were not retarded by VanUG, indicating a key role in VanUG
binding (S1 Fig). The appearance of several DNase I hypersensitive sites (Fig 2B) correspond-
ing to bending of the DNA duplex suggested binding of two VanUG monomers or dimers. This
is consistent with the presence of two inverted repeats in the PUG region (Fig 2A) and with the
two-step gel retardation (S1 Fig). In contrast to VanUG, VanRG and VanRG-P did not bind to
the PUG promoter.
VanUG acts as a repressor of the PUG regulatory promoter
The vanG operon is part of a large genetic element and is transferable from E. faecalis BM4518
to E. faecalis JH2-2 from chromosome to chromosome [11]. Since clinical isolate BM4518 is
not transformable, we studied the VanURSG system in transconjugant BM4522 (JH2-2::vanG)
(S1 Table). To determine the role of VanUG on PUG, the vanUG, vanRG, and vanSG genes of
BM4522 were inactivated individually by in-frame deletions leading to BM4720(ΔvanUG),
BM4721(ΔvanRG), and BM4722(ΔvanSG). Transcription of the regulatory genes was quantified
by RT-qPCR. In BM4522, low level transcription occured at similar levels without and with
VanG-Type Vancomycin Resistance Regulation
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various concentrations of vancomycin indicating that the PUG promoter was not inducible by
vancomycin (Fig 2C). In the absence of vanUG, vanRG and vanSG were transcribed in the ab-
sence or presence of vancomycin at higher level ( 5-fold) from PUG indicating that VanUG
acted as a repressor on this promoter region (Fig 2D). In the absence of vanRG or vanSG, tran-
scription of the regulatory genes remained unchanged even in the presence of vancomycin.
To confirm regulation of PUG by VanUG, the vanURSG genes were cloned into vancomycin
susceptible Escherichia coli NR698 [12] under the control of promoter Pspank upstream from
Fig 2. Binding sites of VanUG to the PUG regulatory promoter (A, B) and regulatory genes transcription
(C, D). (A) Sequence of the PUG region. The transcriptional start site (+1) is in boldface and the -35 and -10
sequences are boxed. The translational start site is in boldface and underlined and the ribosome binding site
(RBS) is in boldface and in italics. Regions protected from DNase I cleavage by VanUG are delineated by a
bracket. The binding motif is composed of two 14-bp imperfect inverted repeats indicated in orange and
purple and by arrows; the complementary bases are underlined. (B) DNase I footprinting analysis of the
binding of VanUG to PUG. A 357-bp DNA fragment was amplified from the PUG promoter region using a
labeled reverse primer (VanG126) to radiolabel the template strand. Increasing amounts of VanUG, indicated
above each lane, were incubated with the DNA probe. The bracket indicates the region protected from
DNase I cleavage by VanUG and the co-ordinates of protection relative to the transcriptional start site are
indicated on the left. M is the A+GMaxam and Gilbert sequencing reaction lane of the probe used as a size
marker and the nucleotide positions are indicated at the right. Transcription of the regulatory genes by RT-
qPCR in transconjugant BM4522 (C) and deletant derivatives relative to the same genes of BM4522 (D). The
strains are indicated at the bottom. Results are presented in arbitrary units normalized to the rpoB transcripts
in the same strain and in BM4522 under similar conditions. Each strain, not induced or induced by
vancomycin, was tested in triplicate in two independent experiments. The bars represent the means and the
error bars the standard deviations; nd, not detectable. NI, not induced. Vm, vancomycin.
doi:10.1371/journal.pgen.1005170.g002
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PUG fused to a chloramphenicol acetyltransferase (CAT) reporter gene, the two promoters
being separated by a transcription terminator (term) (Table 1). Subsequently, each of the three
genes was inactivated. E. coli RNA polymerase bound to the PUG promoter (S2A Fig) which
was active in the new host, in the presence or in the absence of vancomycin (Table 1). CAT was
produced at a maximum level in the absence of vanUG by plasmids pAT952(PspanktermPUGcat),
pAT966(PspankvanRGtermPUGcat), and pAT969(PspankvanRSGtermPUGcat) (Table 1). In con-
trast, in the presence of VanUG, CAT production was decreased to similar basal levels by plas-
mids pAT965(PspankvanUGtermPUGcat), pAT967(PspankvanURGtermPUGcat), and pAT968
(PspankvanURSGtermPUGcat) (Table 1). These results confirmed that VanUG acts as a strong re-
pressor on the PUG promoter.
The VanRGSG two-component system is functional
Transcription of the resistance genes is under the control of VanURSG and, as discussed above,
VanUG negatively autoregulates vanURSG transcription from the PUG regulatory promoter. To
determine if VanRG and VanSG acted as a two-component system and to study the putative in-
teraction of VanUG with these proteins, VanUG, VanRG, and the cytoplasmic histidine kinase
domain of VanSG were purified as C-terminal His-tag proteins (S1 Table). VanSG autopho-
sphorylated in the presence of [γ-32P]-ATP (Fig 3A). When incubated with purified VanUG or
VanRG, phosphorylated VanSG transferred its phosphate group to VanRG (Fig 3B) but not to
VanUG (Fig 3E). Phosphorylation of VanRG was fast and efficient, occurring in less than a min-
ute. To test the phosphatase activity of VanSG, hydrolysis of VanRG-P over time was analysed
in the absence or in the presence of VanSG. Purified [
32P]-VanRG was stable in vitro for at least
30min and then dephosphorylated slowly (Fig 3C); addition of purified VanSG increased de-
phosphorylation only slightly (Fig 3D–3G). These results indicate that VanRSG was functional
and had characteristics similar to those of other VanRS-type two-component systems [7, 9]
and that VanUG did not affect phosphorylation nor dephosphorylation of VanRG and VanSG
(Fig 3E and 3F).
Table 1. CAT specific activities of PUG promoter in E. coliNR698.
CAT speciﬁc activitya
Plasmid Uninduced Vancomycin
pDR111 (Pspank)
b 8 ± 4 11 ± 5
pAT949 (Pspankcat) 360 ± 13 406 ± 22
pAT950 (Pspanktermcat)
c 80 ± 1 91 ± 5
pAT964 (PspankvanUGtermcat) 65 ± 5 64 ± 6
pAT952 (PspanktermPUGcat) 2023 ± 196 2156 ± 105
pAT965 (PspankvanUGtermPUGcat) 134 ± 15 172 ± 12
pAT966 (PspankvanRGtermPUGcat) 1856 ± 125 2064 ± 269
pAT967 (PspankvanURGtermPUGcat) 159 ± 13 146 ± 14
pAT968 (PspankvanURSGtermPUGcat) 115 ± 13 109 ± 13
pAT969 (PspankvanRSGtermPUGcat) 1557 ± 64 1478 ± 100
a Results are expressed in nanomoles of product formed per minute and per milligram of protein in S100 extracts. Induction was performed with
vancomycin (0.25 μg/ml). Data are means ± standard deviation obtained from a minimum of three independent extracts.
b The Pspank promoter is constitutive due to low expression in the absence of induction by IPTG.
C term corresponds to the T4 transcription terminator.
doi:10.1371/journal.pgen.1005170.t001
VanG-Type Vancomycin Resistance Regulation
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VanUG and VanRG bind to overlapping sites of the PYG resistance
promoter
To study the putative binding of VanUG and VanRG to the PYG region and to identify specific
binding sites, DNaseI footprinting experiments were carried out. The inducible PYG promoter
is composed of -35 (AAAACA) and -10 (TACAAT) regions separated by 16 bp which have
similarity with δ70 recognition sequences, although the -35 sequence is not conserved consis-
tent with the fact that the promoter is positively regulated (Fig 4B). Analysis of the PYG region
revealed three 12-bp directly repeated VanRG binding motifs and a deduced consensus se-
quence (T/C)CGTANGAAA(T/A)T was analogous to that in the PR and PH vanA operon
Fig 3. Autophosphorylation of VanSG (A), phosphotransfer from VanSG-P to VanRG (B),
phosphorylation of VanRG by acetyl [
32P] phosphate (C), hydrolysis of VanRG-P by VanSG (D), and
phosphotransfer from VanSG to VanUG (E) or to VanUG plus VanRG (F).Quantitative analysis of
phosphorylated VanRG in panels C and D (G). (A) Purified VanSG was incubated with [γ-
32P]-ATP for 1 h at
room temperature to test autophosphorylation. (B) After autophosphorylation of VanSG (time 0), purified
VanRG was added, samples were removed at the indicated times (in min), mixed with β-mercaptoethanol
stop solution on ice and separated by SDS-PAGE (15%). Transfer of radioactivity to VanRG was revealed by
autoradiography. (C) Purified VanRG was incubated with acetyl[
32P]phosphate for 1 h at room temperature
(time0), excess acetyl[32P]phosphate was removed by using a Sephadex G-50 Quick-Spin column, and
phosphorylated VanRG was incubated at room temperature either alone or (D) following the addition of
purified VanSG. Samples were removed at the indicated times (in min), mixed with β-mercaptoethanol-stop
solution on ice, resolved by SDS-PAGE (15%), and subjected to autoradiography. After autophosphorylation
of VanSG (time 0), purified VanUG was added alone (E) or with VanRG (F), samples were removed at the
indicated times (in min), mixed with β-mercaptoethanol stop solution on ice and separated by SDS-PAGE
(12%). Transfer of radioactivity to VanRG but not to VanUG was revealed by autoradiography. (G) Hydrolysis
in the absence (blue line, panel C) or in the presence (pink line, panel D) of VanSG of purified VanRG labeled
with acetyl[32P]phosphate was detected on a phosphor storage screen and percent quantified. Results are
the means of four independent experiments and the bars indicate standard deviations.
doi:10.1371/journal.pgen.1005170.g003
VanG-Type Vancomycin Resistance Regulation
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promoters [13]. In the PUG region, similar sequences were not found (Fig 2A) which could ex-
plain lack of VanRG binding. The radiolabeled probe corresponding to positions -163 to +69
relative to the transcription initiation point of the PYG promoter and containing the three con-
served sequences was incubated with increasing amounts of purified VanUG, VanRG, and
VanRG-P (Fig 4). The three proteins protected in a concentration-dependent manner an over-
lapping DNA region that included the three direct repeats. The PYG region protected by
VanUG was much larger than that by VanRG and VanRG-P extending from -110 to -3 and
overlapped the -35 sequence at 0.2 and 1μM (Fig 4A, lanes 17 and 18). The PYG region pro-
tected by VanRG and VanRG-P extended from -100 to -56 at low concentration (Fig 4A, brack-
et I, lanes 3 and 8) and from -100 to -43 at higher concentrations (Fig 4A, bracket II, lanes 4
and 5, and 9 and 10). There were three binding motifs a, b, and c with different affinities for
VanRG and VanRG-P in the PYG promoter region (Fig 4). Only a slight difference in affinity in
favor of VanRG-P at 0.2μMwas noted for the "a" site (Fig 4A, lane 2) compared with VanRG
which could be due to inefficient phosphorylation of VanRG by acetylphosphate. VanRG and
VanRG-P bound to the a and b sites (Fig 4A, lanes 2, 3, and 8) with higher affinity than to the c
site (Fig 4A, lanes 4 and 5, and 9 and 10), whereas VanUG bound to this DNA region with the
same affinity (Fig 4A).
VanUG allows rheostatic expression of the resistance genes
To study the consequences of the binding of VanUG and VanRG to overlapping regions of PYG
on the expression of the resistance genes, the VanTG serine racemase was used as a reporter
(Fig 5). In clinical isolate BM4518 and transconjugant BM4522, synthesis of the serine racemase
was dependent on the concentration of vancomycin (Fig 5). In contrast, in BM4720(ΔvanUG),
the resistance operon was expressed at its maximum even at low concentrations of vancomycin.
These results suggested that VanUG acts as a repressor of PYG and that, in its absence, there is
no fine-tuning of resistance expression from this promoter. Thus, modulation of transcription
by vancomycin was due to the phosphorylation level of VanRG mediated by VanSG provided
that VanUG was present. Surprisingly, as in the wild-type strain, induction was dependent on
the concentration of the inducer in BM4721(ΔvanRG) (Fig 5). This could be accounted for by
the presence of a VanR homolog in the host. In fact, we found, in both E.faecalis BM4518 and
transconjugant BM4522 which were entirely sequenced (GenBank N°PRJNA245745), a gene
specifying a VanR'G protein with 65% identity with VanRG (S3A Fig). In BM4722(ΔvanSG)
there was no synthesis of VanTG in the presence of vancomycin indicating that VanRG and
VanR'G are not phosphorylated in the absence of VanSG. Double mutant BM4723(ΔvanRG,
ΔvanR'G) derived from E. faecalis BM4721(ΔvanRG) was susceptible to vancomycin (MIC, 1μg/
ml) and VanTG production was no longer inducible by vancomycin, indicating cross-talk be-
tween VanSG and VanR'G (Fig 5). To avoid interference by this regulator, transcription from
the PYG promoter was studied in E.coliNR698 since E. coli RNA polymerase was able to bind
to this promoter (S2B Fig). The vanURSG, vanRSG, and vanUSG genes were cloned under the
control of Pspank upstream from the PYG transcriptionally fused to a cat gene generating
pAT970 (PspankvanURSGtermPYGcat), pAT971 (PspankvanRSGtermPYGcat), and pAT972
(PspankvanUSGtermPYGcat). In the absence of VanUG, induction by vancomycin led to similar
levels of CAT synthesis in the strain harboring pAT971 (PspankvanRSGtermPYGcat) whatever the
concentration of the inducer, whereas with pAT970 (PspankvanURSGtermPYGcat) CAT produc-
tion depended on the vancomycin concentration (Table 2). These results confirmed that, in the
presence of vancomycin, VanUG is required for rheostatic gene transcription from PYG and that
VanRG phosphorylation is essential for expression of the resistance genes since, in the absence
of this regulator in pAT972 (PspankvanUSGtermPYGcat), the level of CAT activity was low, both
VanG-Type Vancomycin Resistance Regulation
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without (74U±9) and with (104 U ± 13) vancomycin (0.30 μg/ml). In the absence of vancomy-
cin, CAT activity was lower in E. coli producing vanUG encoded by pAT970 (PspankvanURSG-
termPYGcat) than in its counterpart harboring pAT971 (PspankvanRSGtermPYGcat). This
confirms that VanUG acts as a repressor on the PYG resistance promoter (Table 2).
Fig 4. Binding of VanUG, VanRG, and VanRG-P to the PYG resistance promoter. (A) DNase I footprinting
analysis. A 233-bp DNA fragment was amplified from the PYG promoter region using a labeled reverse primer
(YG10) to radiolabel the template strand. Increasing amounts of VanUG, VanRG, or VanRG-P, indicated at the
top, were incubated with the DNA probe. The brackets indicate the regions protected from DNase I cleavage
by VanUG, VanRG, or VanRG-P, and the co-ordinates of protection relative to the transcriptional start site are
indicated on the left. The three 12-bp VanRG binding sites (a, b, c) are indicated in red on the left. The red
asteriks indicate the slight difference in affinity in favor of VanRG-P (lane 2) in comparison with VanRG (lane
7), both at 0.2 μM. M is the A+GMaxam and Gilbert sequencing reaction lane of the probe used as a size
marker and the nucleotide positions are indicated at the right. (B) Sequence of the PYG promoter region. The
transcriptional start site (+1) is in boldface and the -35 and -10 sequences are boxed. The three (a, b, c) 12-bp
putative VanRG binding sites are in blue and indicated by black lines. The region protected from DNase I
cleavage by VanUG is delineated by a black bracket and that of VanRG or VanRG-P is delineated by a
dotted bracket.
doi:10.1371/journal.pgen.1005170.g004
VanG-Type Vancomycin Resistance Regulation
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VanUG and VanRG compete for binding to the PYG resistance promoter
Since VanUG and VanRG bound at overlapping sites of PYG, to assess a possible effect of
VanRG on the binding of VanUG, we performed DNaseI footprinting assays on the labeled PYG
probe with purified VanRG and VanUG (Fig 6). Low and medium concentrations (64 nM and
128 nM) of VanUG which allow binding to PYG were tested with increasing concentrations of
VanRG. Upon addition of VanRG, the binding profile of VanUG faded while that of VanRG ap-
peared and increased in a dose dependent manner (Fig 6A). In the reverse experiment two
approriate concentrations of VanRG were challenged by increasing concentrations of VanUG
and the binding of VanRG decreased also in the presence of VanUG (S4 Fig). In summary,
VanUG alone did not allow transcription of the resistance genes (Fig 6B). It thus appears that
at a low concentration of vancomycin there was competition between VanUG and VanRG, the
latter being partially phosphorylated, transcription of vanYGWGGXYGTG was low. In contrast,
at high concentrations of vancomycin, VanRG was efficiently phosphorylated and able to dis-
place VanUG leading to maximal transcription of the resistance genes from the PYG promoter.
Fig 5. VanTG racemase specific activity in membrane extracts from clinical isolate BM4518,
transconjugant BM4522, and its deletant derivatives. Vancomycin (Vm) inducing concentrations (μg/ml)
and MICs are indicated at the bottom. NI, not induced. The error bars represent the standard deviations from
at least three independent experiments (eight for BM4723) and the values above the bars are the means of
specific activity defined as the number of nanomoles of product formed at 37°C per minute per milligram of
protein contained in the extracts.
doi:10.1371/journal.pgen.1005170.g005
Table 2. CAT specific activities of PYG promoter in E. coliNR698.
Plasmid Vancomycin
0 0.2 0.3 0.4
pAT970 (PspankvanURSGtermPYGcat) 264 ± 23
a 566 ± 54 797 ± 64 1283 ± 118
pAT971 (PspankvanRSGtermPYGcat) 544 ± 48 1585 ± 115 1556 ± 162 1487 ± 142
a Results are expressed in nanomoles of product formed per minute and per milligram of protein in cytoplasmic extracts. Data are means ± standard
deviation obtained from a minimum of three independent extracts.
b The Pspank promoter is constitutive due to low expression in the absence of induction by IPTG.
C term corresponds to the T4 transcription terminator.
doi:10.1371/journal.pgen.1005170.t002
VanG-Type Vancomycin Resistance Regulation
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The presence of vanUG reduces the fitness cost associated with
expression of VanG-type resistance
To study the role of VanUG in this sophisticated resistance mechanism, the fitness cost of
BM4720(ΔvanUG) compared with that of BM4522 in monocultures in the absence and in the
presence of vancomycin (1 μg/ml) was analysed by determination of the growth rates (Table 3).
The results showed that the growth rates of both strains were indistinguishable in the absence of
vancomycin indicating that non induced VanG-type resistance is not costly for the host. In con-
trast, in the presence of vancomycin, the relative growth rate of BM4720(ΔvanUG) (0.74) was
Fig 6. Competition between VanUG and VanRG for binding to the PYG resistance promoter. (A) DNase I
footprinting analysis. A 233-bp DNA fragment was amplified from the PYG region using a labeled reverse
primer (YG10) (S2 Table) to radiolabel the template strand. Increasing amounts of VanRG and two fixed
amounts of VanUG, indicated at the top, were incubated with the DNA probe. The bracket indicates the region
protected from DNase I cleavage by VanUG and/or VanRG and the co-ordinates of protection relative to the
transcriptional start site are indicated on the left. M is the A+GMaxam and Gilbert sequencing reaction lane of
the probes used as a size marker and the nucleotide positions are indicated at the right. (B) Model for the
binding competition between VanUG and VanRG-P in the absence or in the presence of various
concentrations of vancomycin (Vm).
doi:10.1371/journal.pgen.1005170.g006
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significantly reduced when compared with that of BM4522 (0.93) indicating that increased ex-
pression of resistance was significantly more costly in the absence of vanUG.
Discussion
Among the ubiquitous two-component regulators, VanR/VanS-type systems are one of the
rare to control expression of genes mediating antibiotic resistance [3]. In the VanG-type
strains, a membrane associated sensor kinase (VanSG) which detects a signal associated with
the presence of vancomycin in the environment and a cytoplasmic response regulator (VanRG)
that acts as a transcriptional activator are also present (Fig 1) and functional (Fig 3) but there
is, in addition, a VanUG transcriptional regulator (Fig 1).
In the two main VanA- and VanB-type systems, the regulatory genes (vanRS) and the resis-
tance genes are transcribed from independent and coordinately regulated promoters, but VanR
is the only known direct regulator of the resistance genes [3, 8, 13]. In VanG-type strains, co-
transcription of vanURSG is repressed from PUG by VanUG (Fig 2 and Table 1) and expression
of the resistance genes from PYG is activated by VanRG and repressed by VanUG (Fig 5 and
Table 2). Thus, VanUG regulates the resistance genes both directly, by binding to the PYG pro-
moter region (Fig 4), and indirectly by repressing synthesis of VanRGSG (Fig 5). Like other
members of the XRE protein family (S3B Fig) [14–16], VanUG binds to short repeated se-
quences which span the promoters (Fig 2A and 2B). Unlike the VanR and VanRB proteins
which bind to their own promoters [8, 13], VanRG does not regulate its own expression (Fig 2).
No sequences similar to the VanRG consensus binding site are found in PUG (Figs 2 and 4).
VanRG, as VanR and VanRB, belongs to the OmpR-PhoB subclass of response regulators
that have the peculiarity to bind to their target promoters in the unphosphorylated or phos-
phorylated form [8, 13, 17, 18]. Phosphorylation of VanR and VanRB enhances the affinity of
the proteins for their respective regulatory PR or PRB and resistance PH or PYB promoter regions
allowing increased transcription of the regulatory and resistance genes [8, 13]. In VanA-type
strains, VanR and VanR-P bind to PR and PH regions which contain a single or two 12-bp con-
served sites, respectively [13]. Comparison of the sequences of the PUG and PYG regions with
the 12-bp consensus sequence spanned by VanR and VanR-P revealed three binding sites in
the PYG region with a consensus sequence (Fig 4B) similar to that in VanA-type resistance [13].
As for the regulatory PR and resistance PH promoters, the positioning of these sites in PYG was
upstream from the -35 motif. VanUG, VanRG, and VanRG-P protected overlapping regions,
the two latter binding to PYG a and b sites with a higher affinity than to the c site (Fig 4). There
are only two sites in the PH promoter but VanR generated a more extensive footprint (80 bp for
PH) than VanRG (42bp for PYG) likely due to higher cooperativity of VanR. Although not es-
sential for binding in vitro, phosphorylation of VanRG increased its affinity for the PYG resis-
tance promoter (Fig 4). In the PUG promoter region no sequences similar to the consensus
Table 3. Growth rate.
Growth rate a Relative growth rateb
Strain NI Vm1
E. faecalis BM4522 0.027 ± 0.001 0.025 ± 0.001 0.926
E. faecalis BM4720 (ΔvanUG) 0.027 ± 0.001 0.020 ± 0.002 0.741
a Exponential growth rate measured in the absence of antibiotic or in the presence of vancomycin (1μg/ml) (Vm1); average of at least four independent
experiments ± standard deviations.
b Relative growth rate was calculated as the ratio of the growth rate of the strain induced by 1μg/ml of vancomycin versus the non induced strain.
doi:10.1371/journal.pgen.1005170.t003
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were found (Fig 2A) which could explain the absence of binding of VanRG and low-level tran-
scription from the regulatory promoter.
In many instances, regulation of gene transcription in E.coli occurs essentially through con-
trol of the phosphatase activity of the sensor [19, 20]. In VanA- and VanB-type strains, the
level of phosphorylation of VanR and VanRB is modulated by the kinase and phosphatase ac-
tivities of the VanS and VanSB sensors [7, 10, 21]. Phosphatase activity is critical for response
regulators, such as VanR and VanRB, whose phosphorylated form is highly stable, to ensure
that the protein is not permanently activated. In VanG-type strains, in the absence of VanUG,
induction by vancomycin led to maximal VanTG serine racemase (Fig 5) or CAT synthesis
(Table 2) even at low concentrations of the inducer. Since in the absence of VanUG there was
no modulation of resistance genes transcription from the PYG promoter, this suggests that a
low amount of VanRG-P is sufficient to induce the resistance operon. VanUG did not modulate
VanRG and VanSG phosphorylation (Fig 4F) and was not phosphorylated by VanSG (Fig 4E).
Surprisingly, at least in vitro, the phosphatase activity of VanSG was not very efficient (Fig 4D)
in comparison with those of VanS or VanSB [7, 9]. Expression of VanG-type resistance was
thus inducible by vancomycin due to the presence of VanUG as opposed to direct modulation
of VanR activity by VanS in the other van operons. In the absence of vancomycin only VanUG
bound to the PYG promoter; however when the concentration of vancomycin increased, VanRG
being more efficiently phosphorylated by VanSG, displaced progressively VanUG allowing
gradual transcription of the resistance genes (Fig 6) as it is likely the case with VanR'G, the
VanRG homolog encoded elsewhere in the chromosome. In B. subtilis, when both repressors
SinR and SlrR are bound to the degU promoter, they can be displaced by the response regulator
DegU leading to activation of the degU gene [22]. Also in B. subtilis, CcpC activates aconitase
gene citB expression whereas CodY binds to its promoter and represses citB transcription [23];
PutR which is an activator essential for transcription of the putBCP operon for proline utiliza-
tion is displaced by the CodY repressor [24].
VanUG does not possess the characteristics of auxiliary regulators which can interact with
histidine kinases, influencing signal perception and transduction. Nor does it interact with the
response regulator to alter its phosphorylation status or its DNA binding ability, the recruite-
ment of RNA polymerase on the promoter, or to sequester it through protein:protein interac-
tion [25, 26]. The results presented here show that competition between the VanUG repressor
and the VanRG activator for binding to the PYG promoter may be responsible for the complex
regulation of the resistance genes (Fig 6). This is an unusual example of rheostatic regulation of
gene transcription due to binding competition between two regulators encoded in the same op-
eron. It also elucidates an unsuspected strategy by which enterococcal clinical isolates regulate
transcription of acquired genes for vancomycin resistance.
In previous work, we showed in VanB-type resistance that, despite the complex dual bio-
chemical mechanism of resistance to vancomycin, its biological cost in enterococci is negligible
when non induced, whereas a significant fitness reduction is observed when resistance is express-
ed in the presence of the inducer, the antibiotic itself [27]. Thus resistance is expressed exclusively
when needed for bacterial survival. In VanG-type strains, tight regulation of resistance expres-
sion involves VanUG which can thus be considered as a compensatory component, drastically re-
ducing the biological cost associated with vancomycin resistance in the presence of antibiotic.
Materials and Methods
Bacterial strains, plasmids, and growth conditions
The origin and properties of the strains and plasmids are described in S1 Table. Escherichia coli
TOP10 (Invitrogen, Groningen, The Netherlands) and NR698 (susceptible to vancomycin) [12]
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were used as a host for recombinant plasmids. E. coli BL21λDE3 [28], in which the T7 RNA po-
lymerase gene is under the control of the inducible lacUV5 promoter carries the pREP4 plasmid
allowing co-expression of the GroESL chaperonin to optimize recombinant protein solubility
[29]. E. coli TG1 RepA [30] was used as a host for constructions in the pAT944(pGhost9Ocat)
vector (S1 Table). Kanamycin (50μg/mL) was used as a selective agent for cloning PCR products
in the pCR-Blunt vector (Invitrogen). Ampicillin was used to select pUC1813 [31]. pDR111
(gift from David Rudner, Harvard University), which harbors the Pspank promoter between two
fragments of the B.subtilis amyE gene, is a derivative of the Pspac-hy plasmid pJQ43 containing an
additional lacO binding site to achieve a better repression in the absence of the IPTG inducer.
Pspank is a lacI repressible IPTG inducible-promoter for gene overexpression. Spectinomycin
(60μg/mL) and chloramphenicol (10μg/mL) were added to the medium to prevent loss of plas-
mids derived from pDR111(Pspank) and pAT944(pGhost9Ocat), respectively. Enterococcus fae-
calis JH2-2 is a derivative of strain JH2 that is resistant to fusidic acid and rifampin [32]. In all
experiments, strains were grown in brain heart infusion (BHI) at 37°C with shaking at 110 rpm.
Promoter DNA labeling
Labeled PUG (357 bp) and PYG (233 bp) fragments were generated by PCR with BM4518 total
DNA as a template and primer pairs VanG12-VanG126 and VanSG6-YG10 (S2 Table), respec-
tively, using a combination of an unlabeled primer with an end-labeled primer (625nM) with
T4 polynucleotide kinase (0.075 U/μl) (New England Biolabs) and [γ32P]-ATP (3000 Ci/mmol)
(Perkin Elmer). The PCR reactions were carried out in a 50-μl volume and the products purified
as described [8].
Gel shift assay
Purified labeled PCR products corresponding to wild-type and mutated PUG promoter region
fragments were recovered from a 6% polyacrylamide gel and used as a probe for the gel shift
assay after addition of 100 μl of ammonium acetate (0.5 M) diluted in Tris buffer (10 mM,
pH8.5) overnight at 37°C. The PUG and mutated PUG probes (10,000cpm each) were incubated
with various concentrations of purified VanUG regulator at 30°C for 20min in 20 μl of 50mM
Tris-HCl (pH7.8) containing 20 mMMgCl2 and 0.1 mM dithiothreitol (DTT). After addition
of the DNA dye solution (40% glycerol, 0.025% bromophenol blue and 0.025 xylene cyanol),
the mixture was loaded on a 7.5% polyacrylamide gel in the absence of protein denaturants.
The gels were dried and analysed by autoradiography.
DNase I footprinting
Complexes with the labeled promoter regions (5nM) were formed for 30 min at 30°C in 15 μl
of buffer C (20 mMHepes pH 8.0, 5 mMMgCl2, 50 mM potassium glutamate, 5 mMDTT,
and 500μg/ml bovine serum albumin) using RNA polymerase of E. coli at 50 nM or VanUG,
VanRG, or VanRG-P at increasing concentrations. For DNase I experiments, 1.5 μl of DNase I
solution (1 μg ml-1 in 10 mM Tris-HCl, 10 mMMgCl2, 10 mM CaCl2, 125 mM KCl) were
added and incubated at 30°C for 10s when the labeled promoter regions were alone, or for 20 s
when when RNA polymerase or VanUG, VanRG or VanRG-P were present in the mixture. The
reaction was stopped and all the samples were extracted, precipitated, washed, resuspended,
and loaded on a sequencing gel as described [8]. Protected bands were identified by comparing
the migration with that of the same fragment treated for the A+G sequencing reaction [33].
The gels were analysed by autoradiography.
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Quantitative real-time RT-qPCR
Enterococci grown in 100 ml of brain heart infusion in 250-ml bottles, with and without vanco-
mycin, at 37°C with shaking at 110 rpm to OD600 = 0.8 were harvested. RNA was prepared using
the Fast RNA ProBlue kit (MBP Biomedicals) according to the manufacturer's protocol, treated
with DNase (Turbo DNA-free, Invitrogen), and checked for the absence of contaminant DNA in
a standard PCR, using the same primers as for the RT-PCR. RNA concentrations were deter-
mined by measuring absorbance with a NanoDrop2000 (ThermoScientific). cDNA synthesis
and RT-qPCR were performed with a Light Cycler RNA amplification kit SYBR greenI (Roche
Diagnostic GmbH) in a total reaction volume of 19μl with 0.5 μM gene-specific primers
(VanG129-VanG102 for vanUG, VanRG2-VanRG10 for vanRG, VanSG2-VanSG10 for vanSG,
and rpoB5-rpoB12 for rpoB) (S2 Table) according to the manufacturer's instructions. Amplifica-
tion and detection of specific products were performed using the LightCycler sequence detection
system (Roche) with the following cycle profile: 1cycle at 55°C for 20 min for the reverse tran-
scription step, followed by 1 cycle at 95°C for 30 s, 45 cycles at 95°C for 5 s, 52°C for 15 s, and
72°C for 15 s. The level of every gene transcript was normalized relative to rpoB transcript levels.
Overproduction and purification of VanUG, VanRG, and VanSG
Plasmids pAT940(pET28ΩvanUG), pAT941(pET28ΩvanRG), and pAT942(pET28ΩvanSG)
(S1 Table) were introduced into E. coli BL21λDE3/pREP4 [29]. The transformants were grown
in 1 liter of LB medium in Fernbach flasks with shaking at 110 rpm at 28°C until OD600 = 0.8,
IPTG (1 mM) was added to induce protein production, and incubation was pursued for 4 h. E.
coli crude protein extracts were loaded on 1-ml His-Trap fast-flow columns (GE, Healthcare)
equilibrated with buffer A (50mMNaH2PO4 pH 7.5, 300 mMNaCl, 30 mM imidazole) and
the proteins were eluted with an imidazole gradient (30mM-500mM). Fractions were dialysed
against buffer B (50mMNaH2PO4 pH 7.5, 300 mMNaCl, 50% glycerol). Protein concentration
was determined using the Bio-Rad protein assay [34].
Autophosphorylation of VanSG
Autophosphorylation of VanSG (40 μg) was performed in a final volume of 100 μl of buffer A
(final concentrations: 50 mM Tris-HCl, 50mM KCl and 1 mMMgCl2, pH7.5). The reaction
was initiated by the addition of 5 μl of ATP (1mM final) containing 200 μCi of [γ-32P]ATP
and incubated at room temperature for 1 h. ATP was removed using 500 μl Sephadex G-50
spin column equilibrated with buffer A. The reaction was quenched by the addition of 5 μl of
β-mercaptoethanol-stop solution (Sigma), followed by electrophoresis on 12% NuPAGE
Novex Bis-Tris gels (Invitrogen) in MOPS buffer (1X), and autoradiography.
Phosphorylation of VanUG and VanRG by VanSG
Phosphotransfer to purified VanUG and VanRG were carried out in buffer A. The reaction was
initiated by the addition of 10 μl of the purified autophosphorylation reaction mixture of
VanSG (40 μg) described above to a 15 μl reaction mixture containing VanUG or VanRG (55 μg
each). After incubation for various periods of times at room temperature, the phosphotransfer
reactions were quenched by the addition of stop solution (Sigma) followed by electrophoresis
on 12% NuPAGE Novex Bis-Tris gels (Invitrogen) in MOPS buffer (1X) and autoradiography.
Phosphorylation of VanUG and VanRG by acetyl[
32P]phosphate
VanUG (220 μg) or VanRG (225 μg) were incubated in 100 μl of buffer B (50 mM Tris-HCl,
pH7.8, 20 mMMgCl2, 0.1 mM dithiothreitol) containing 178 pmol (3.3 μCi) of acetyl[32P]
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phosphate (Hartmann Analytical, Germany) at room temperature for 60 min. Excess acetyl
[32P]phosphate was removed using Sephadex G-50 spin columns equilibrated with buffer B.
Aliquots (10 μl) were withdrawn at designated time points, and the phosphorylation reactions
were quenched with β-mercaptoethanol-stop solution followed by electrophoresis on 15%
SDS-polyacrylamide gels and autoradiography.
Hydrolysis of phospho-VanUG and phospho-VanRG by VanSG
The VanUG (220 μg) and VanRG (225 μg) response regulators were labelled with acetyl[
32P]
phosphate for 1 h at room temperature as described above, and 52 μg of VanSG histidine kinase
were added, and incubation was pursued for various periods of times. Aliquots (10 μl) were
withdrawn at designated time points and the reactions were stopped, followed by electrophore-
sis on 15% SDS-polyacrylamide gels and autoradiography.
Plasmid construction
The plasmids were constructed as follows.
Construction of pAT940, pAT941 and pAT942. pAT940(pET28ΩvanUG) and pAT941
(pET28ΩvanRG). A 225-bp BsaI-XhoI fragment corresponding to the vanUG coding sequence
amplified with UG1 and UG2 (S2 Table) and a 705-bp BsaI-XhoI fragment corresponding to the
vanRG coding sequence amplified by using oligonucleotides RG1 and RG2 (S2 Table) and
BM4518 [11] total DNA as a template, were cloned in the NcoI and XhoI sites of modified
pET28 [35] to generate plasmids pAT940(pET28ΩvanUG) and pAT941(pET28ΩvanRG).
Oligodeoxynucleotide UG1 contained a BsaI restriction site designed to generate a cohesive
end compatible withNcoI and 16 bases complementary to codons 1–6 of vanUG of BM4518
(S2 Table). Oligodeoxynucleotide UG2 contained a XhoI site replacing the TGA stop codon and
21 bases complementary to codons 69–75 of vanUG. Oligodeoxynucleotide RG1 contained a
BsaI restriction site designed to generate a cohesive end compatible with NcoI and 16 bases com-
plementary to codons 1–6 of vanRG of BM4518. Oligodeoxynucleotide RG2 contained a XhoI
site replacing the TGA stop codon and 21 bases complementary to codons 229–235 of vanRG.
pAT942(pET28ΩvanSG). A cytoplasmic portion of the vanSG gene of strain BM4518 was
amplified using BM4518 total DNA as a template and primer pair SG1-SG3 (S2 Table). Oligo-
deoxynucleotide SG1 contained a BsaI restriction site designed to generate a cohesive end com-
patible withNcoI, and 16 bases complementary to codons 88–93 of vanSG. Oligodeoxynucleotide
SG3 contained a XhoI site in place of the TAG stop codon and 21 bases complementary to co-
dons 361–367 of vanSG. The 842-bp pCR product from vanSG was digested by BsaI and XhoI
and cloned between the NcoI and XhoI restriction sites of plasmid pET28 to generate plasmid
pAT942(pET28ΩvanSG).
Construction of pAT944(pGhost9Ocat). The XbaI cassette containing the chloramphen-
icol acetyltransferase cat gene with its own promoter was amplified from DNA of plasmid
pAT943(pUC1318OPcat) with primers pG9CATNH2 and pG9CATCOOH (S2 Table) which con-
tain a XbaI restriction site allowing the replacement of the XbaI fragment containing the eryth-
romycin resistance gene in pGhost9 [36] to generate plasmid pAT944(pGhost9Ocat).
Construction of pAT945(pGhost9CmOΔvanUG), pAT946(pGhost9CmOΔvanRG),
pAT947(pGhost9CmOΔvanSG,), and pAT973(pGhost9CmOΔvanR'G). The vanUG, vanRG,
and vanSG genes of the vanG operon and vanR'G from BM4518 were inactivated by deletion
using splicing-by-overlap extension PCR in two steps and cloned into the thermosensitive
shuttle plasmid pAT944(pGhost9Ocat) using XhoI and PstI restriction sites to generate plas-
mids pAT945(pGhost9CmOΔvanUG), pAT946(pGhost9CmOΔvanRG), pAT947(pGhost9C-
mOΔvanSG), and pAT973(pGhost9CmOΔvanR'G). The primers used for the construction of
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the deletant alleles and the extent of the deletions are reported in S2 Table. A SmaI restriction
site was added in the primers to screen for integration in the corresponding chromosomal
gene. Briefly, the remnants of the vanUG, vanRG, vanSG and vanR'G genes of BM4518 were first
amplified from total DNA of BM4518 as a template using primers UG3-UG4 and UG5-UG6
for ΔvanUG, UG3-RG4 and RG5-RG7 for ΔvanRG, SG4-SG5 and SG6-SG7 for ΔvanSG,
RG10-RG11 and RG12-RG13 for ΔvanR'G and, in a second step, the resulting PCR products
were amplified with UG3 plus UG6, UG3 plus RG7, SG4 plus SG7, and RG10 plus RG13 re-
spectively, to obtain ΔvanUG, ΔvanRG, ΔvanSG and ΔvanR'G.
Construction of pAT949 and derivatives. Plasmid pAT949(pDR111OPspankcat) was con-
structed by cloning the HindIII-SphI fragment of pAT948(pUC1813Ocat) carrying the cat cas-
sette in pDR111(Pspank) digested with the same enzymes allowing a directional cloning of the
cat reporter gene under the control of the inducible Pspank promoter.
pAT950 (pDR111OPspanktermcat). A 66-bp HindIII-SalI fragment corresponding to the
transcription terminator of gene 32 from bacteriophage T4 [37] was amplified by PCR with oli-
godeoxynucleotides T4F-HindIII and T4R-SalI/NheI (S2 Table). Primer T4F-HindIII con-
tained HindIII and NheI restriction sites. Primer T4R-SalI/NheI contained SalI and NheI
restriction sites. The HindIII and SalI restriction sites allowed directional cloning of the tran-
scription terminator (term) from bacteriophage T4 under the control of the inducible Pspank
promoter and upstream from the cat reporter gene of the pAT949(pDR111OPspankcat)
shuttle vector.
pAT951(pDR111OPspankvanUGcat). The vanUG gene of BM4518 was amplified using
primer pair UGNH2 and UGCOOH (S2 Table) and total DNA of the corresponding strain as a
template. Oligodeoxynucleotide UGNH2 contained BsaI and HindIII restriction sites, a RBS,
and 6 bases complementary to vanUG including the ATG (translation initiation) codon. Oligo-
deoxynucleotide UGCOOH harbored SalI and NheI restriction sites, the stop codon, and 15
bases complementary to the 3’ end sequence of vanUG from BM4518. The BsaI and SalI restric-
tion sites allowed directional cloning of a 249-bp fragment of vanUG downstream from the in-
ducible Pspank promoter and upstream from the cat gene of the pAT949(pDR111OPspankcat)
shuttle vector to generate pAT951(pDR111OPspankvanUGcat).
pAT952(pDR111OPspanktermPUGcat) and pAT953(pDR111OPspankvanUGPUGcat). The
regulatory PUG (183 bp) promoter was amplified by PCR from BM4518 total DNA with oligo-
deoxynucleotides PUG1 and PUG2 (S2 Table). Primers PUG1 and PUG2 contained a NheI and
a SalI restriction site, respectively, which allowed directional cloning of PUG upstream from the
cat gene of pAT950(pDR111OPspanktermcat) to generate pAT952(pDR111OPspanktermPUGcat)
or allowed directional cloning of PUG downstream from vanUG and upstream from the cat re-
porter gene of pAT951(pDR111OPspankvanUGcat) to generate pAT953
(pDR111OPspankvanUGPUGcat).
pAT954(pDR111OPspankvanRGPUGcat). A 754-bp HindIII-NheI fragment correspond-
ing to the vanRG coding sequence with its RBS, initiation and stop codons was amplified by
PCR from BM4518 with oligodeoxynucleotides RGNH2 and RGCOOH (S2 Table). Primer
RGNH2 contained a HindIII restriction site. Primer RGCOOH comprised SalI and NheI restric-
tion sites, the stop codon, and 14 bases complementary to the 3’ end of vanRG from BM4518.
The HindIII and NheI restriction sites allowed directional cloning of the vanRG gene under the
control of the inducible Pspank promoter and upstream from PUG and the cat gene of pAT952
(pDR111OPspanktermPUGcat).
pAT956(pDR111OPspankvanURGPUGcat), pAT958(pDR111OPspankvanRSGPUGcat),
pAT960(pDR111OPspankvanURSGPUGcat) pAT961(pDR111OPspankvanRSGPYGcat)and
pAT962(pDR111OPspankvanURSGPYGcat). The vanURG, vanRSG, and vanURSG genes
of BM4518 were amplified using primer pairs UGNH2-RGCOOH, RGNH2-SGCOOH, and
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UGNH2-SGCOOH (S2 Table), respectively, and BM4518 total DNA as a template. Oligodeoxy-
nucleotides UGNH2 and RGNH2 harbored a HindIII restriction site and 21 bases complemen-
tary to the sequence upstream from vanUG or 17 bases complementary to the sequence
upstream from vanRG. Primers RGCOOH and SGCOOH contained each SalI and NheI restric-
tion sites, the stop codon and 14 or 13 bases complementary to the 3' end of respectively
vanRG and vanSG of BM4518. The HindIII and SalI restriction sites allowed directional clon-
ing of vanURG, vanRSG, and vanURSG upstream from the cat reporter gene of shuttle vector
pAT949(pDR111OPspankcat) carrying the inducible Pspank promoter to generate pAT955
(pDR111OPspankvanURGcat), pAT957(pDR111OPspankvanRSGcat), and pAT959
(pDR111OPspankvanURSGcat). The 183-bp NheI-SalI fragment carrying the PUG promoter
obtained above by amplification was cloned in pAT955(pDR111OPspankvanURGcat), pAT957
(pDR111OPspankvanRSGcat), and pAT959(pDR111OPspankvanURSGcat) digested with
the same enzymes to generate pAT956(pDR111OPspankvanURGPUGcat), pAT958
(pDR111OPspankvanRSGPUGcat), and pAT960(pDR111OPspankvanURSGPUGcat). The
177-bp NheI-SalI fragment carrying the PYG resistance promoter amplified by PCR
from BM4518 DNA with primers PYG1 and PYG2 (S2 Table) was cloned in pAT957
(pDR111OPspankvanRSGcat), and pAT959(pDR111OPspankvanURSGcat) digested with
the same enzymes to generate, respectively, pAT961(pDR111OPspankvanRSGPYGcat)and
pAT962(pDR111OPspankvanURSGPYGcat).
pAT964(pDR111OPspankvanUGtermcat), pAT965(pDR111OPspankvanUGtermPUGcat),
pAT966(pDR111OPspankvanRGtermPUGcat), pAT967(pDR111OPspankvanURGtermPUGcat),
pAT968(pDR111OPspankvanURSGtermPUGcat), pAT969(pDR111OPspankvanRSGtermPUGcat),
pAT970(pDR111OPspankvanURSGtermPYGcat), and pAT971 (pDR111OPspankvanRSGterm-
PYGcat). The NheI terminator fragment amplified by PCR with oligodeoxynucleotides T4F-NheI
and T4R-NheI/KpnI (S2 Table) was cloned, respectively, in pAT951(pDR111OPspankvanUGcat),
pAT953(pDR111OPspankvanUGPUGcat), pAT954(pDR111OPspankvanRGPUGcat), pAT956
(pDR111OPspankvanURGPUGcat), pAT960(pDR111OPspankvanURSGPUGcat), pAT958
(pDR111OPspankvanRSGPUGcat), pAT962(pDR111OPspankvanURSGPYGcat) and pAT961
(pDR111OPspankvanRSGPYGcat) digested with NheI.
pAT972(pDR111OPspankvanUSGtermcat). The 1,144-bp fragment containing the vanSG
gene of BM4518 was amplified using primer pair SGNH2-SGCOOH (S2 Table) and total DNA of
the corresponding strain as a template. The NheI and SalI restriction sites allowed directional
cloning of vanSG downstream from the vanUG gene and upstream from the cat gene of
pAT951(pDR111OPspankvanUGcat) to generate pAT963(pDR111OPspankvanUSGcat).
The EcoRI fragment harboring the vanUSG' genes from pAT963(pDR111OPspankvanUSGcat)
was replaced by the EcoRI fragment carrying the vanRSG' genes of pAT971(pDR111OPspankvan-
RSGtermPYGcat) to generate pAT972(pDR111OPspankvanUSGtermcat).
Construction of strains
Plasmids pDR111, pAT949, pAT950, pAT952, pAT964, pAT965, pAT966, pAT967, pAT968,
pAT969, pAT970, pAT971, and pAT972 were introduced by transformation into vancomycin
susceptible E. coliNR698 and transformants were selected on agar containing chloramphenicol
(10 g/ml) or ampicillin (100 μg/ml, for pDR111) (Tables 1 and 2).
In Gram-positive bacteria, pGhost9 [36] which replicates at 28°C but is lost above 37°C, al-
lowed construction of E.faecalis BM4522 derivatives by insertional inactivation. Plasmids
pAT945(pGhost9CmOΔvanUG), pAT946(pGhost9CmOΔvanRG), and pAT947(pGhost9C-
mOΔvanSG) were electrotransformed into E. faecalis BM4522 [11] to generate, respectively,
BM4720(ΔvanUG), BM4721(ΔvanRG), and BM4722(ΔvanSG) (S1 Table). Plasmid pAT973
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(pGhost9CmOΔvanR'G) was electrotransformed into E. faecalis BM4721(ΔvanRG) to generate
the double mutant BM4723(ΔvanRG, ΔvanR'G). Transformants were selected at the permissive
temperature (28°C) on M17 plates containing 10g/ml of chloramphenicol and 0.5% glucose. A
colony of each transformant was inoculated into 50 ml of M17 broth containing 0.5% glucose
and incubated for 2h at 28°C. The culture was then shifted to a non-permissive temperature
(42°C) for 2 h and integrants, following a first recombination event, were selected at 42°C on
M17 agar containing chloramphenicol (10g/ml). Plasmid excision, by a second recombination
event, was favored by subculturing at 28°C in the absence of chloramphenicol and plasmid loss
was screened for by plating at 42°C onM17-glucose followed by replica plating on chlorampheni-
col. The integration locus was determined by PCR following digestion with SmaI and sequencing.
Enzyme assays
For preparation of extracts, 8 ml of an overnight culture were added to 100 ml of broth in the
absence or in the presence of vancomycin and strains were grown until OD600 = 0.8 in 250 ml
bottles with shaking at 110 rpm. The cells were harvested by centrifugation, washed in 0.1M
phosphate buffer pH 7.0, resuspended in the same buffer, lysed by sonication, followed by cen-
trifugation at 10,000 g during 45 min. The resuspended pellet for VanTG racemase [11] and su-
pernatant for CAT activity, were assayed as described [38].
Genome sequencing, assemblies and annotation
Total DNA from BM4518 and BM4522 strains was purified and sequencing library prepara-
tion was carried out using the Nextera DNA Sample Preparation kit (Illumina, San Diego,
CA), according to manufacturer’s specifications. Quality and quantity of each sample library
was measured on an Agilent Technologies 2100 Bioanalyzer (Santa Clara, CA). Libraries
were normalized to 2nM, multiplexed and subjected to 250-bp paired end sequencing (Illu-
mina MiSeq). On average, 5 million high-quality paired-end reads were collected for each
strain, representing>220-fold coverage of the ~2.9 Mb genomes. Reads were assembled de
novo utilizing CLC Genomics Workbench (CLC bio, Cambridge, MA). Functional annota-
tions were performed using a custom pipeline as described previously [39].
Determination of growth rates
Growth rates were determined in microplates coupled to a spectrophotometer iEMS reader
(Labsystems). Strains were grown overnight at 37°C without or with 1 μg/ml of vancomycin.
The cultures were diluted at OD 0.15 into 10 ml of broth without or with vancomycin (1μg/ml)
and grown at 37°C with shaking until the beginning of the stationary phase. The cultures were
diluted 1/1,000 to inoculate 105 bacteria into 200 μl of broth in a 96-well microplate that was
incubated overnight at 37°C with shaking. Absorbance was measured at 600 nm every 3 min.
Each culture was replicated three times in the same microplate. Growth rates performed in
three independent experiments were determined at the beginning of the exponential phase and
the relative growth rates were calculated as the ratio of the growth rate of the strain induced by
vancomycin versus that of the non induced strain.
Supporting Information
S1 Fig. Effect of mutations in the PUG promoter regulatory region on the in vitro binding
of VanUG. (A) Sequence of the wild-type (WT) and mutated promoter regions. The two 14-bp
imperfect inverted repeats corresponding to the putative binding sites are indicated in orange
and pink and by arrows. A DNA fragment (197 bp) was obtained with PUG3 plus labeled
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VanG126 and mutated PUG5 plus labeled VanG126 primers (S2 Table) leading to the WT and
corresponding mutated (mutant 1) promoter region, respectively. A DNA fragment (293 bp)
was obtained with labeled VanG12 plus PUG4 and labeled VanG12 plus mutated PUG6 prim-
ers (S2Table) leading to the WT and corresponding mutated (mutant 2) promoter region, re-
spectively. Numbering relative to the transcription start site is indicated above the sequences.
Only bases differing from the WT sequence are shown in the mutated fragments. (B) Gel shift
analysis. The labeled fragments corresponding to the WT and mutated (mutant 1 and mutant
2) promoter regions were incubated in the absence or in the presence of decreasing concentra-
tions of purified VanUG protein indicated above the lanes.
(TIF)
S2 Fig. Binding of δ70 RNA polymerase of E. coli to (A) the PUG regulatory and (B) PYG
resistance promoters by DNase I footprinting analysis. (A) A 357-bp DNA fragment was am-
plified from the PUG promoter region using a labeled reverse primer (VanG126) (S2 Table) to ra-
diolabel the template strand and the DNA probe was incubated without and with δ70 RNA
polymerase at 50 nM. (B) A 233-bp DNA fragment was amplified from the PYG promoter region
using a labeled reverse primer (YG10) (S2 Table) to radiolabel the template strand and the DNA
probe was analysed similarly. The brackets indicate the regions protected from DNase I cleavage by
δ70 RNA polymerase, and the co-ordinates of protection relative to the transcriptional start site are
indicated on the right. M is the A+GMaxam and Gilbert sequencing reaction lane of the probes
used as a size marker and the nucleotide positions are indicated at the left. RNAP,
RNA polymerase.
(TIF)
S3 Fig. Comparison of the deduced amino acid sequences of VanRG with VanR'G (A) and
of VanUG from E. faecalis BM4518 with Cro/CIcd from Clostridium difficile (77% identity,
GenBank N° EQJ96019) and Cro/CIbf from Butyvibrio fibrisolvens (52% identity, GenBank
N° WP_022757627) (B). Identical amino acids are indicated by dashes below the alignment.
(DOC)
S4 Fig. Competition between VanRG and VanUG for binding to the PYG resistance pro-
moter by DNase I footprinting. A 233-bp DNA fragment was amplified from the PYG region
using a labeled reverse primer (YG10) (S2 Table) to radiolabel the template strand. Increasing
amounts of VanUG and two fixed amounts of VanRG indicated at the top were incubated with
the DNA probe. The bracket indicates the region protected from DNase I cleavage by VanRG
and/or VanUG and the co-ordinates of protection relative to the transcriptional start site are in-
dicated on the left. M is the A+GMaxam and Gilbert sequencing reaction lane of the probes
used as a size marker and the nucleotide positions are indicated at the right.
(TIF)
S1 Table. Bacterial strains and plasmids.
(DOC)
S2 Table. Oligonucleotide primers used.
(DOC)
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